TrueParallel, Author at AskBio - Page 2 of 4

AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint Posted on January 4, 2024 (January 4, 2024) by TrueParallel in News&Uncategorized
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P) Posted on November 17, 2023 (January 4, 2024) by TrueParallel in News&Uncategorized
Updated AskBio Leadership Structure Reflects Strategic Focus Posted on October 13, 2023 (October 13, 2023) by TrueParallel in News&Uncategorized
AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) Posted on August 3, 2023 (August 3, 2023) by TrueParallel in News&Uncategorized
AskBio Vice President and Neurobiology Sector Lead Nathalie Cartier Honored with Ann B. Moser Award Posted on November 18, 2022 (November 18, 2022) by TrueParallel in News
Selecta and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR in Gene Therapy Posted on February 17, 2021 (February 17, 2021) by TrueParallel in News
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy Posted on January 28, 2021 by TrueParallel in News
Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics Posted on January 12, 2021 (January 12, 2021) by TrueParallel in News
AskBio Applauds Commencement of Pfizer’s Pivotal Trial for Duchenne Muscular Dystrophy Posted on January 8, 2021 (January 27, 2021) by TrueParallel in News
AskBio Welcomes Brain Neurotherapy Bio to Expand Clinical Pipeline for Neurodegenerative Diseases Posted on December 16, 2020 (January 28, 2021) by TrueParallel in News